Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying
Jasmijn D E de Rooij1, Cristyn Branstetter2, Jing Ma3
1Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.
Abstract:
Acute megakaryoblastic leukemia (AMKL) is a subtype of acute myeloid leukemia (AML) in which cells morphologically resemble abnormal megakaryoblasts. While rare in adults, AMKL accounts for 4-15% of newly diagnosed childhood AML cases. AMKL in individuals without Down syndrome (non-DS-AMKL) is frequently associated with poor clinical outcomes. Previous efforts have identified chimeric oncogenes in a substantial number of non-DS-AMKL cases, including RBM15-MKL1, CBFA2T3-GLIS2, KMT2A gene rearrangements, and NUP98-KDM5A. However, the etiology of 30-40% of cases remains unknown. To better understand the genomic landscape of non-DS-AMKL, we performed RNA and exome sequencing on specimens from 99 patients (75 pediatric and 24 adult). We demonstrate that pediatric non-DS-AMKL is a heterogeneous malignancy that can be divided into seven subgroups with varying outcomes. These subgroups are characterized by chimeric oncogenes with cooperating mutations in epigenetic and kinase signaling genes. Overall, these data shed light on the etiology of AMKL and provide useful information for the tailoring of treatment.
Insights
This study reveals that pediatric acute megakaryoblastic leukemia (AMKL) without Down syndrome is diverse, with seven subgroups identified. These groups feature oncogenes and cooperating mutations, impacting treatment strategies.
Area of Science:
- Hematology
- Genomics
- Oncology
Background:
- Acute megakaryoblastic leukemia (AMKL) is a rare AML subtype, particularly in children.
- Non-Down syndrome AMKL (non-DS-AMKL) often has poor outcomes.
- Known genetic alterations explain only a portion of non-DS-AMKL cases.
Purpose of the Study:
- To investigate the genomic landscape of non-DS-AMKL.
- To identify novel genetic drivers and understand the heterogeneity of this leukemia.
- To provide insights for personalized treatment approaches.
Main Methods:
- RNA and exome sequencing were performed on 99 non-DS-AMKL patient specimens (75 pediatric, 24 adult).
- Genomic data were analyzed to identify chimeric oncogenes and cooperating mutations.
- Subgroup analysis was conducted to correlate genetic profiles with clinical outcomes.
Main Results:
- Pediatric non-DS-AMKL is genetically heterogeneous, divisible into seven distinct subgroups.
- These subgroups are characterized by specific chimeric oncogenes.
- Cooperating mutations in epigenetic regulators and kinase signaling pathways were identified within subgroups.
Conclusions:
- The study elucidates the complex genomic underpinnings of non-DS-AMKL.
- Identified subgroups offer a framework for understanding disease heterogeneity and prognosis.
- Findings support the development of targeted therapies for specific AMKL subgroups.
More Related Videos
08:31Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018